“Active” Cancer Immunotherapy by Anti-Met Antibody Gene Transfer
Open Access
- 14 November 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (22), 9176-9183
- https://doi.org/10.1158/0008-5472.can-08-1688
Abstract
Gene therapy provides a still poorly explored opportunity to treat cancer by “active” immunotherapy as it enables the transfer of genes encoding antibodies directed against specific oncogenic proteins. By a bidirectional lentiviral vector, we transferred the cDNA encoding the heavy and light chains of a monoclonal anti-Met antibody (DN-30) to epithelial cancer cells. In vitro, the transduced cells synthesized and secreted correctly assembled antibodies with the expected high affinity, inducing down-regulation of the Met receptor and strong inhibition of the invasive growth response. The inhibitory activity resulted (a) from the interference of the antibody with the Met receptor intracellular processing (“cell autonomous activity,” in cis) and (b) from the antibody-induced cleavage of Met expressed at the cell surface (“bystander effect,” in trans). The monoclonal antibody gene transferred into live animals by systemic administration or by local intratumor delivery resulted in substantial inhibition of tumor growth. These data provide proof of concept both for targeting the Met receptor and for a gene transfer–based immunotherapy strategy. [Cancer Res 2008;68(22):9176–83]Keywords
Other Versions
This publication has 41 references indexed in Scilit:
- The Met tyrosine kinase receptor in development and cancerCancer and Metastasis Reviews, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America, 2007
- Novel antibodies as anticancer agentsOncogene, 2007
- A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivoClinical Cancer Research, 2006
- Comparing antibody and small-molecule therapies for cancerNature Reviews Cancer, 2006
- Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.Clinical Cancer Research, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Stable antibody expression at therapeutic levels using the 2A peptideNature Biotechnology, 2005
- HighIn VivoProduction of a Model Monoclonal Antibody on Adenoviral Gene TransferHuman Gene Therapy, 2002
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996